Tag: medical

Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
—Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—

Louvain-La-Neuve, Belgium, June 25, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Fundação Severino Sombra (FUSVE), a non-profit philanthropic healthcare and educational institution responsible for the University of Vassouras and Hospital Mário Kroeff, for the purchase of a Proteus^®ONE¹ system.

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Therapeutic Apheresis Market size & share revenue was valued at approximately USD 3.84 Billion in 2025 and is expected to reach USD 4.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 7.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Terumo BCT Inc., Fresenius Kabi AG, Haemonetics Corporation, B. Braun Melsungen AG, Asahi Kasei Medical Co. Ltd., Miltenyi Biotec GmbH, Nikkiso Co. Ltd., Kaneka Corporation, Mallinckrodt Pharmaceuticals (Uvadex/ECP), Photomedex Inc., Macopharma SAS and others.

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding memorandum of understanding (the “MOU”) setting out the principal commercial terms for a proposed definitive distribution agreement (the “Definitive Agreement”) with ExoLyra LLC, which operates as an arm’s length third party (“ExoLyra”).